Return to search results
Quizartinib
VANFLYTA (quizartinib) is an oral prescription tablet developed by Daiichi Sankyo Inc. for treating certain blood cancers. It works as a kinase inhibitor targeting FLT3 mutations, available in 17.7 mg and 26.5 mg strengths. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | VANFLYTA (quizartinib) is an oral prescription tablet developed by Daiichi Sankyo Inc. for treating certain blood cancers. It works as a kinase inhibitor targeting FLT3 mutations, available in 17.7 mg and 26.5 mg strengths. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Quizartinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Quizartinib — ANDA 216993 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216993"
}
]
|
| identifier | ANDA216993 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-safety",
"fda",
"health-care",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Quizartinib |
